BioSpace News Archive

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted 11 new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $18.44, which was the closing price on August 8, 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock.

HeartBeam, Inc. (NASDAQ: BEAT) today announced the publication of a foundational study demonstrating the ability of its VECG platform to detect the presence of coronary artery blockages.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q2 2023 operational and financial results on Tuesday, August 15, 2023 at 8:30 AM ET.

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport and storage of drugs and vaccines, today announced the appointment of drug delivery and healthcare innovation veteran, Brian Bernick, MD, as Chairman of the company’s Board of Directors.

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.

Medical device maker CEFALY Technology will present findings from the TEAM study at the Military Health System Research Symposium August 14-17, 2023, in Kissimmee, FL.

Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, today announced it received expanded CE (Conformité Européenne) mark approval under MDR European regulation for Nerivio® as dual-use therapy for both acute and preventive treatment of migraine for adults and adolescents.

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the addition of three new therapy products centered around pain management.

The Stock Day Podcast welcomed MIRA Pharmaceuticals, Inc.(Nasdaq:MIRA) (“the Company”), a pre-clinical-stage pharmaceutical development company developing a Novel synthetic THC analog.

Mekonos, Inc., a biotech platform company building the future of cell therapies on a chip, today announced the appointment of Benjamin Borgo, MBA, PhD, as chief operating officer.